Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEG002 in Relapsed/Refractory Multiple Myeloma
NCT04688853Phase 1Unknown
- Sponsor
- Gadeta
- Start
- May 2021
- Primary completion
- Jul 2023
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TEG002 in multiple myeloma (MM), sponsored by Gadeta. Primary endpoints: Incidence of Adverse Events and Dose-Limiting Toxicities at Day 28 and Long-term Safety Confirmation at 2 years. Status: unknown.
02
Drugs
TEG002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04688853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688853.